VEOZA

VEOZA™ (fezolinetant) is an innovative healthcare solution developed by Astellas Pharma, specifically designed for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. As a first-in-class selective neurokinin 3 (NK3) receptor antagonist, VEOZA effectively targets specific neurons in the hypothalamus to alleviate the discomfort caused by VMS, offering a non-hormonal approach to symptom management.

Clinically demonstrated to provide significant reductions in the frequency and severity of VMS within 24 hours, VEOZA shows promise for postmenopausal women seeking relief from these challenging symptoms. The product is available in 45 mg film-coated tablets and is subject to strict monitoring due to associated safety considerations.

Astellas Pharma is dedicated to advancing women's health, ensuring healthcare professionals have access to ongoing resources, dosing guidelines, and vital product information. With a commitment to research and development, VEOZA stands as a relevant option in the current therapeutic landscape for managing menopausal symptoms. For more detailed information, please visit Astellas Pharma's dedicated site for healthcare providers.